| Generic name | Polatuzumab vedotin-piiq |
| Brand name(s), other common name(s) | PolivyTM |
| Drug type | CD79b-directed antibody–drug conjugate |
| How the drug is given | Intravenous |
Indications and Usage
Polatuzumab vedotin-piiq is FDA approved in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least two prior therapies.
Accelerated approval was granted for this indication based on complete response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Side effects needing medical attention
The most common adverse reactions included neutropenia, thrombocytopenia, anemia, peripheral neuropathy, fatigue, diarrhea, fever, decreased appetite, and pneumonia.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.